Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy

Massimiliano Bonifacio,Luigi Scaffidi,Gianni Binotto,Maria Cristina Miggiano, Marco Danini,Claudia Minotto,Davide Griguolo,Luciana Marin,Luca Frison,Fabio D’Amore,Marco Basso,Roberto Sartori,Martina Tinelli,Manuela Stulle, Stefania Fortuna,Angela Bonalumi, Giovanni Bertoldero,Ercole De Biasi,Marco Ruggeri,Gianpietro Semenzato

Leukemia Research（2018）

引用 13|浏览53

暂无评分

摘要

•In CML patients, switch from branded to generic imatinib appears to be safe.•New or worsening side effects, mostly grade 1–2, were reported by 17% of patients.•Molecular responses remained stable or continued to improve on generic imatinib.•Few patients needed to switch back to branded imatinib or move to other TKIs.

查看译文

关键词

Generic imatinib,Branded imatinib,Adverse events,Molecular response,Savings

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要